Navigation Links
Zymes LLC, University of Windsor and National Research Council of Canada Collaborative Research Presented at the 2010 Experimental Biology Meeting in Anaheim, California
Date:5/11/2010

HASBROUCK HEIGHTS, N.J., May 11 /PRNewswire/ -- Scientists from Zymes LLC, the University of Windsor (Ontario, Canada) and the National Research Council of Canada presented their research at the 2010 Experimental Biology meetings in Anaheim California on April 28th.  The paper entitled, "Protection of SNpc neurons by water soluble CoQ10 in a paraquat induced rat model of Parkinson's disease: The role of neurotrophic factors," describes a potential treatment for halting the progression of Parkinson's disease in an animal model using Zymes' water soluble CoQ10 (WS-CoQ10) formulation.  

Parkinson's disease (PD) is a neurodegenerative disorder that results from the progressive loss of select neurons in the brain.  Many studies show that mitochondrial dysfunction/oxidative stress is a major contributor to this disease.  An established animal model of paraquat-induced Parkinson's disease was used in this study.  Animals were given Zymes' water soluble CoQ10 in their drinking water with access 24 hours a day pre-treatment (prophylactic) and post-treatment (therapeutic). In these studies, Zymes' water soluble CoQ10 provided significant protection of dopaminergic neurons and a decrease in symptoms.  

"We are very excited about these early stage findings that support the use of Zymes' water soluble CoQ10 to halt the symptoms of Parkinson's disease," said Dr. Shelley Weinstock, Sr. VP of Research and Scientific Affairs.  In addition, in these studies, animals were exposed to the water soluble CoQ10 on a continuous basis in their water, suggesting that small doses, several times a day is a more effective method of administration than larger doses once or twice per day.  More research is needed to determine if Zymes' water soluble CoQ10 may be effective in halting the progression of Parkinson's disease in people.

About Zymes LLC:

Zymes LLC is a bioscience company based in Hasbrouck Heights, NJ that provides innovative solutions to its partners and consumers through proprietary science and technology, enabling new products to enhance the well-being of people. For more information please visit www.zymes.com.


'/>"/>
SOURCE Zymes LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Novozymes Launches Enzyme to Reduce Acrylamide in Food
2. Genencor Appoints New Executive Vice President - Technical Enzymes
3. DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production
4. ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4
5. Novozymes Reports Strong 2008 Results
6. Albemarle Manufactures Zymes PTS, the Lead Compound in a Breakthrough Solubilization Technology
7. Zymes Omega Solutions Bottles and Launches the Worlds First Omega-3 Enhanced Water
8. Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement
9. Reportlinker Adds Industrial Enzymes - A Global Market Report
10. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
11. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 ... ... announces publication of a United States multicenter, prospective clinical study that demonstrates ... point-of-care diagnostic test capable of identifying clinically significant acute bacterial and viral ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
Breaking Biology Technology:
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Biology News(10 mins):